- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AGI THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HARROW | 50,23 | +2,20 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 84,66 | +0,46 % | Cantor Fitzgerald bestätigt "Overweight" für Bright Minds Biosciences und sieht Potenzial in Hauptwirkstoff BMB-101 | ||
| MILESTONE PHARMACEUTICALS | 2,075 | +6,41 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| LB PHARMACEUTICALS | 22,020 | -0,59 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,975 | +1,79 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,803 | -22,82 % | Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update | Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR, in the U.S. in December 2025
CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 8,000 | -6,76 % | Kazia Therapeutics Limited: Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 17,010 | +2,78 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,278 | -13,48 % | Reviva Pharmaceuticals: Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia | Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 4,690 | +1,63 % | NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards | EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's... ► Artikel lesen | |
| OMNIAB | 1,960 | +1,03 % | OmniAb outlines $18M-$22M 2025 revenue guidance while launching OmniUltra and expanding xPloration platform | ||
| TRISALUS LIFE SCIENCES | 7,060 | +0,14 % | TriSalus Life Sciences stock maintains Buy rating at Canaccord on strong growth | ||
| VYNE THERAPEUTICS | 0,572 | +0,70 % | VYNE Therapeutics und Yarrow Bioscience fusionieren in 200-Millionen-Dollar-Transaktion | ||
| PROCESSA PHARMACEUTICALS | 3,510 | +4,46 % | PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study | ||
| JOURNEY MEDICAL | 8,130 | +2,14 % | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen |
AGI THERAPEUTICS PLC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGI THERAPEUTICS PLC finden Sie auf Wallstreet Online.